For the quarter ended June 2026, Teleflex (TFX Quick QuoteTFX - Free Report) reported revenue of $570.33 million, down 27% over the same period last year. EPS came in at $1.76, compared to $3.73 in the year-ago quarter.

The reported revenue represents a surprise of +1.89% over the Zacks Consensus Estimate of $559.76 million. With the consensus EPS estimate being $1.28, the EPS surprise was +37.5%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Teleflex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Interventional: $211.9 million compared to the $221.52 million average estimate based on nine analysts.
• Revenues- Surgical: $112.1 million compared to the $104.61 million average estimate based on nine analysts. The reported number represents a change of -1.7% year over year.
• Revenues- Vascular: $246.3 million versus $233.04 million estimated by nine analysts on average.

View all Key Company Metrics for Teleflex here>>>

Shares of Teleflex have returned +4.9% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.